deltatrials
Terminated PHASE1 INTERVENTIONAL 1-arm NCT02908451

A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer

A Phase I Dose Escalation Study, With Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients With Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, Pancreatic or Biliary Cancer

Sponsor: AbGenomics B.V Taiwan Branch

Conditions Biliary Cancer Colorectal Cancer Gastric Cancer Pancreatic Cancer
Interventions AbGn-107
Updated 17 times since 2017 Last updated: Jul 8, 2021 Started: Apr 24, 2017 Primary completion: Feb 28, 2021 Completion: Feb 28, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

COVID-19 pandemic has caused a huge operational difficulty for this ongoing clinical trial, as many hospitals have set limitations on onsite staff, patient visits, study related procedures and onsite monitoring visits.

Other terminated trials from AbGenomics B.V Taiwan Branch

More terminations from AbGenomics B.V Taiwan Branch

Other Biliary Cancer trials with similar outcome

Browse all Biliary Cancer trials

Listed as NCT02908451, this PHASE1 trial focuses on Biliary Cancer and Colorectal Cancer and remains terminated or withdrawn. Sponsored by AbGenomics B.V Taiwan Branch, it has been updated 17 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Sep 2019 · 7 months · monthly snapshot~Sep 2019 – ~Jan 2020 · 4 months · monthly snapshot~Jan 2020 – ~Aug 2020 · 7 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

17 versions recorded

  1. Dec 2025 — Present [monthly]

    Terminated PHASE1

  2. Sep 2025 — Dec 2025 [monthly]

    Terminated PHASE1

  3. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  5. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE1

▶ Show 12 earlier versions

  1. Sep 2021 — Dec 2021 [monthly]

    Terminated PHASE1

    Status: Active Not Recruiting → Terminated

  2. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1

  3. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  4. Jan 2020 — Aug 2020 [monthly]

    Recruiting PHASE1

  5. Sep 2019 — Jan 2020 [monthly]

    Recruiting PHASE1

  6. Feb 2019 — Sep 2019 [monthly]

    Recruiting PHASE1

  7. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE1

  8. Nov 2018 — Jan 2019 [monthly]

    Recruiting PHASE1

  9. Jun 2018 — Nov 2018 [monthly]

    Recruiting PHASE1

  10. Jul 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  11. Feb 2017 — Jul 2017 [monthly]

    Not Yet Recruiting PHASE1

  12. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbGenomics B.V Taiwan Branch
Data source: AbGenomics B.V Taiwan Branch

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations